Clinical Trial Update: Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for vorasidenib in pediatric patients with IDH1/IDH2-mutant grade II astrocytoma or oligodendroglioma; the study is not yet recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Astrocytoma Grade Ii
• Oligodendroglioma

Drugs mentioned

• Vorasidenib (vorasidenib)

Snippet

Sponsor: Institut de Recherches Internationales Servier (I.R.I.S.) | Conditions: Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation | Phase 2 | Status: NOT_YET_RECRUITING